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The increasing resistance to macrolide, lincosamide, and streptogramin B agents
among methicillin-resistant Staphylococcus aureus (MRSA) is a worldwide problem for
the health community. This study aimed to investigate the prevalence of ermA, ermB,
ermC, and msrA in MRSA strains isolated from burn patients in Ahvaz, southwest of
Iran. A total of 76 isolates of S. aureus were collected from January to May 2017 from
Taleghani Burn Hospital in Ahvaz. Among 76 S. aureus strains collected, 60 (78.9%)
isolates wereMRSA. The antimicrobial susceptibility testing for MRSA showed extreme
high resistance rate to clarithromycin (100%) and azithromycin (100%), followed by
erythromycin (98.3%). The PCR assay revealed that the frequency rates of msrA, ermA,
and ermC genes were 23 (38.3%), 28 (46.7%), and 22 (36.7%), respectively. In addition,
none of the MRSA isolates had the ermB gene. Because of the high prevalence of
macrolide and lincosamide resistance found in MRSA isolates from infections of burn
patients in Ahvaz, southwest of Iran, it is recommended that local periodic survey be
performed for controlling the dissemination of antimicrobial resistance.
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Introduction
Infection is the most serious complication among burned patients, which is
difficult to control and remains to be the leading cause of morbidity and mortality
in these patients. In addition, invasive infections caused by antibiotic-resistant
bacteria, which are responsible for 28%–65% of burn deaths globally, should be
considered as a potential risk and their resistance pattern must be identified as soon
as possible [1, 2].
Staphylococcus aureus is known to be one of the most common burn wound
pathogens worldwide. Colonization of S. aureus on the surface of burn wounds
could be associated with delayed wound healing, increased treatment costs
through the need for expensive antibiotics, prolonged duration of stay at burn
centers, and increased need for surgical interventions [3, 4].
Since the discovery of the first effective antimicrobials in medical science, S.
aureus has demonstrated rapid development of antibiotic resistance, as well as
developed resistance to the most variety of antibiotics [5]. Although β-lactam
antibiotics are the main compounds utilized to treat staphylococci-related infec-
tions, the emergence of methicillin-resistant S. aureus (MRSA) and alterations in
antimicrobial resistance pattern has caused renewed interest in the use of anti-
biotics, such as macrolide, lincosamide, and streptogramin B (MLSB), for the
treatment of these infections [6].
This group of antibiotics, in spite of their different chemical structure, has a
similar mode of action and has been classified in the same group. They inhibit
protein synthesis by binding to the subunit 23S rRNA of the bacterial 50s
ribosomal subunits [7]. Among MLSB, clindamycin, due to its pharmacokinetic
properties such as good oral absorption, excellent penetration in the skin, and
tolerability, is a frequent choice for some staphylococcal infections, particularly
skin and soft-tissue infections. However, extensive use of these antibiotics has led
to the emergence of resistance to them [8].
Resistance to MLSB antibiotics among staphylococci more often involves
the following two mechanisms, such as the active efflux of the antimicrobial agent
by an ATP-dependent pump encoded bymsrA gene and the ribosomal binding site
modification by 23S rRNAmethylases mediated by one or more erm genes (ermA,
ermB, ermC, and ermF) among which ermA and ermC are predominant genes [9].
Mechanism of ribosomal target site modification can be either constitutive or
inducible. S. aureus isolates with constitutive resistance show resistance to
erythromycin and clindamycin on in vitro testing, whereas isolates with inducible
resistance show resistance to erythromycin but appear sensitive to clindamycin on
disk diffusion testing [10, 11]. The aim of this study was to investigate the
molecular detection of MLSB resistance genes (ermA, ermB, ermC, mecA, and
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msrA) and antibiotic resistance profiles in MRSA strains isolated from burn
patients using polymerase chain reaction (PCR) technique in southwest Iran.
Materials and Methods
Bacterial isolates
In this cross-sectional study, clinical samples were collected from burn
patients, admitted to the Taleghani Burn Hospital, Ahvaz, Iran, from January to
May 2017. The research was approved by the ethical committee of Ahvaz
Jundishapur University of Medical Sciences, Khuzestan, Iran. As a part of the
Ahvaz Jundishapur University of Medical Sciences policy, written informed
consent was obtained from all patients. The study was conducted in accordance
with the Declaration of Helsinki. The specimens included were urine, blood,
abscess, deep wound, and endotracheal secretion. The samples were cultured on
10% sheep blood agar and Mannitol salt agar (Merck, Darmstadt, Germany).
Presumptive staphylococcal colonies (growth on mannitol salt agar, Gram-
positive, and catalase-positive cocci) were tested for production of DNase and
coagulase. Isolates with positive reactions (DNase-positive and coagulase-
positive) were considered as S. aureus [12].
Cefoxitin and oxacillin disk diffusion method
Susceptibility tests for S. aureus isolates were performed by the Kirby–
Bauer disk diffusion method as recommended by Clinical and Laboratory
Standards Institute (CLSI) using oxacillin (1 μg) and cefoxitin (30 μg) disks.
The inhibition zones for the oxacillin disk with diameter ≤10 mm for S. aureus
were considered to be resistant and the inhibition zone for cefoxitin with diameters
of ≥20 and ≤19 mm were considered susceptible and resistant, respectively [13].
Epsilometer test
The Epsilometer test (E-test) was conducted for quantitative antimicrobial
susceptibility testing using E-test strips (Liofilchem, Italy). A standard bacterial
suspension equal to 0.5 McFarland inoculated on Mueller–Hinton agar (MHA)
plates; then, E-test strips of tigecycline, linezolid, teicoplanin, vancomycin, and
quinupristin/dalfopristin were placed on the medium surface and incubated at 35 °C
for 24 h for detection of minimum inhibitory concentration (MIC). The MIC was
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read at the lowest concentration at which the border of the elliptical inhibition zone
intercepted the scale on the strip.
Oxacillin–salt agar screening
The presence of MRSA was confirmed by oxacillin–salt agar screening test.
This test was performed according to CLSI recommendations [13]. For each
isolate, 1 ml of standard 0.5 McFarland suspension was cultured on an MHA
medium containing oxacillin (at a concentration of 6 μg/ml of media) and
4% NaCl. The plates were incubated in ambient air at 35 °C for 24 h. Any
growth on the plate was indicated as oxacillin resistance.
MRSA antibiotic susceptibility pattern
Susceptibility testing of MRSA isolates against erythromycin (15 μg),
clarithromycin (15 μg), azithromycin (15 μg), vancomycin (30 μg), clindamycin
(2 μg), linezolid (30 mg), teicoplanin (30 μg), trimethoprim/sulfamethoxazole
(1.25/23.75 μg), quinupristin/dalfopristin (15 μg), tigecycline (15 μg), gentamicin
(10 μg), and rifampin (5 μg) disks (Mast, Merseyside, United Kingdom) was
determined by the Kirby–Bauer disk diffusion method on MHA, according to the
procedures described by the CLSI guidelines. On following this, inducible
clindamycin resistance was determined using the D-zone test according to these
guidelines [13]. S. aureus ATCC 25923 was used as the reference strain.
Amplification of 16S rRNA gene specific for S. aureus and ermA, ermB, ermC,
mecA, and msrA genes
DNA was extracted from bacterial colonies by the simple boiling method as
previously described [4]. In brief, a few bacterial colonies were suspended in
400 ml of tris ethylene diaminetetraacetic acid buffer (pH 8.0), and the solution
was heated at 100 °C for 10 min and then centrifuged at 15,000 rpm for 15 min.
The supernatant was used as template DNA in PCR.
The PCR assay was performed in 25 μl contained a DNA template (50 ng),
100 μM concentrations (each) of the four dNTPs, 1 U of Taq DNA polymerase
(Cinnagen, Iran), 5 μl of Taq buffer (5×), 25 pM of each of forward and reverse
primers ermA, ermB, ermC, andmsrA (Table I). The PCR mixtures were subjected
to thermal cycling (4 min at 94 °C, followed by 30 cycles of 30 s at 94 °C for
denaturation, 30 s for annealing extension, and extension at 72 °C for 30 s). A final
elongation at 72 °C for 5 min was achieved in a DNA thermal cycler [14].
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PCR products were analyzed by 1% agarose gel electrophoresis in 1× tris-borate-
EDTA buffer at pH 8.3. The amplification products were photographed and their
size was determined using a 100-bp molecular size marker [14].
Statistical analysis
Descriptive data were analyzed using SPSS v.22.0 statistics software (IBM
Corporation, Armonk, NY, USA). χ2 and t-tests were used to analyze intergroup
significance. In addition, p< 0.05 was considered statistically significant.
Results
Bacterial isolates
From the total screened samples during 6 months, 76 S. aureuswere isolated by
biochemical tests and 16S rRNA gene PCR. Using cefoxitin and oxacillin disk
diffusion and oxacillin–salt agar screening and PCR for themecA gene, 60 (79%) of S.
aureus were identified as being methicillin-resistant. Out of 60 MRSA isolates
studied, 34 (56.7%) and 26 (43.3%) strains were collected from male and female
patients, respectively. The sample sources according to the hospital wards were as
follows: the internal women, internal men, pediatric, intensive care unit, and surgery,
repair, and outpatient department (OPD), with proportions of 6 (10%), 12 (20%),
9 (15%), 26 (43.3%), 2 (3.3%), 4 (6.7%), and 1 (1.7%), respectively. About 88.3%
(53/60) of isolates were obtained from wound culture specimens, 1 (1.7%) from urine
culture, 3 (5%) from blood culture, and 3 (5%) from endotracheal secretion culture.
Table I. Primers and their target genes used in this study
Primer Sequence (5′–3′) Product size (bp) Reference
16S rRNA F: GAA AGC GTG GGG ATC AAA CA 340 [15]
R: TTG CGG GAC TTA ACC CAA CA
ermA F: GAT TTC GTT CCT CGA CC 139 [15]
R: TAT CTT ATC GTT GAG AAG GGA TT
ermB F: CTA TCT GAT TGT TGA AGA AGG ATT 142 [15]
R: TTT ACT CTT GGT TTA GGA TGA AA
ermC F: CTT GTT GAT CAC GAT AAT TTC C 190 [15]
R: ATC TTT TAG CAA ACC CGT ATT C
msrA F: TCC AAT CAT TGC ACA AAA TC 163 [16]
R: AAT TCC CTC TAT TTG GTG GTC
mecA F: ACGGTAACATTGATCG-CAACG 176 [15]
R: GGCCAATTCCACATTGTTTCG
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Antibiotic resistance pattern
According to disk diffusion results, all MRSA strains were resistant to
clarithromycin and azithromycin. In addition, the majority of the strains was resistant
to erythromycin 59 (98.33%), clindamycin 56 (93.3%), and trimethoprim/
sulfamethoxazole 58 (96.67%), whereas, using the E-test, all MRSA isolates were
susceptible to teicoplanin with a maximum range 0.25 (MIC≤ 4 mg/ml), linezolid=
0.19 (MIC≤ 4 mg/ml), vancomycin= 0.5 (MIC≤ 2 mg/ml), and tigecycline= 0.25
(MIC≤ 4 mg/ml) and showed resistance to oxacillin (MIC≥ 4 mg/ml). Besides, the
D-test results showed that 30 (50%) of the MRSA isolates have the inducible
clindamycin resistance phenotype. The resistance profile for all isolates to macrolides
and other tested antibiotics is listed in Table II. Fifty-nine (98.3%) isolates were
simultaneously resistant to erythromycin, azithromycin, and clarithromycin (cross-
resistance); whereas only 1 (1.7%) isolate had various macrolide susceptibility pattern.
This isolate was susceptible to erythromycin and was resistant to azithromycin and
clarithromycin. The highest antimicrobial resistance was related to wound specimens
with 100% resistance to erythromycin, clarithromycin, and azithromycin and 93.3%
resistance to clindamycin.
MDR profiles
The results of the susceptibility testing showed that all 60 MRSA isolates
were resistant to at least two antibiotics, and the majority of isolates (N= 58,
96.6%) was multidrug-resistant (MDR) with five diverse patterns (Table III).
Table II. Prevalence of resistance to the tested antibiotics among MRSA isolates using the disk diffusion
and t-test methods
Antibiotics Resistant no. (%) Intermediate no. (%) Susceptible no. (%)
Erythromycin 59 (98.33) 0 1 (1.67)
Clarithromycin 60 (100) 0 0
Azithromycin 60 (100) 0 0
Vancomycin 0 0 60 (100)
Clindamycin 56 (93.3) 0 4 (6.67)
Linezolid 0 0 60 (100)
Teicoplanin 0 0 60 (100)
Trimethoprim/sulfamethoxazole 58 (96.67) 2 (3.33)
Quinupristin/dalfopristin 0 0 60 (100)
Tigecycline 0 0 60 (100)
Rifampin 9 (15) 0 51 (85)
Gentamicin 40 (66.6) 0 20 (33.3)
Note: MRSA: methicillin-resistant Staphylococcus aureus.
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MRSA isolates were screened for the presence of ermB, ermA, ermC, and
msrA genes as the main causative agents of resistance to macrolides. The
frequency rates of msrA, ermA, and ermC genes in MRSA isolates were
23 (38.3%), 28 (46.7%), and 22 (36.7%), respectively. In addition, 32 (53.3%)
MRSA isolates harbored at least one of the four investigated genes. Seventeen
(28.3%) macrolide-resistant MRSA harbored ermA, msrA, and ermC genes
simultaneously.
In contrast, the ermB gene was absent in all MRSA isolates. All (100%)
msrA-, ermA-, and ermC-positive isolates were resistant to clarithromycin,
azithromycin, and erythromycin and 98.33% of clindamycin-resistant isolates
harbored genes of ermA and msrA. Statistical analyses showed that among the
MRSA isolates, difference in prevalence of ermA, ermC, and msrA genes was
significant in clarithromycin- and clindamycin-resistant MRSA isolates.
Discussion
S. aureus remains a major cause of wound infection in patients with burn
injuries [17]. Infection by MRSA has been observed to be higher than 50% in burn
units. The increase in antibiotic resistance of this pathogen involved in wound
infections is a great therapeutic problem and worsens the prognosis of burn
patients [18]. The high frequency of infections caused by MRSA and its diverse
antimicrobial resistance patterns had led to the use of MLSB antibiotics in the
Table III. Multidrug-resistant profiles of methicillin-resistant Staphylococcus aureus isolates
Multidrug-resistant profile Phenotypic resistance Number of isolates (%)
I ERY–CLR–AZM–SXT 2 (3.3)
II ERY–CLR–AZM–CLI–SXT 16 (26.6)
III ERY–CLR–AZM–CLI–SXT–GEN 30 (50.0)
IV ERY–CLR–AZM–CLI–SXT–RIF–GEN 9 (15.0)
V CLR–AZM–CLI–SXT–GEN 1 (1.6)
Note: ERY: erythromycin; CLR: clarithromycin; AZM: azithromycin; CLI: clindamycin; SXT:
trimethoprim–sulfamethoxazole; RIF: rifampicin; GEN: gentamicin.
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treatment of these infections [19]. At present, the widespread use of these
antibiotics in treatment of infections caused by S. aureus has led to the emergence
of MLSB-resistant strains [19, 20].
In this study, 79% of the isolated S. aureus strains was identified as MRSA
by the application of the cefoxitin disk and oxacillin–salt agar screening, which is
comparable to the 77.9% prevalence of MRSA in Iranian burn patients [21]. In a
study from capital of Iran, Abbasian et al. [22] reported prevalence rate of 64.2%
for MRSA in a burn hospital. The prevalence rate of MRSA in Iranian burn centers
is different in various regions. However, several studies revealed the increasing
prevalence of MRSA in our country [21]. These inconsistencies in the prevalence
of MRSA among various regions might be due to the different antibiotic use
patterns and dissimilar infection control strategies [22].
In this study, according to results of disk diffusion testing, most of the
MRSA isolates showed high resistance rate to macrolide antibiotics including
100% resistance against clarithromycin and azithromycin and 98.3% against
erythromycin, respectively. In a previous study performed by Seifi et al. [23],
lower resistance rate (88.6%) was reported for erythromycin in clinical isolates of
MRSA. In this study, similar to the previous report by Goudarzi et al. [14], the
majority of the erythromycin-resistant isolates had cross-resistance to other
macrolides. This study revealed a high level of resistance to clindamycin
(93.3%) that was similar to the study from a regional burn center in Southeastern
China [24]. Furthermore, this study indicated that more than 90% of MRSA
isolates were MDR (resistance to three or more unique antimicrobial drug classes),
which were in accordance with the results of another investigation from Iran
carried out by Goudarzi et al. [25].
Moreover, our finding revealed that the vancomycin, linezolid, teicoplanin,
and tigecycline were the most effective antibiotics against MRSA that was parallel
with the findings reported by Amissah et al. [1] and Ohadian Moghadam et al.
[26]. Therefore, the mentioned antibiotics can still be used for treatment of the
infections caused by MRSA in burn patients in our region. In contrast to another
report from Iran [25], our results showed low frequency of resistance to
quinupristin/dalfopristin (10%) and rifampicin (15%) in MRSA isolates that is
probably due to the low prescribing of these antibiotics in our region.
In this study, the molecular assay identified the ermA gene as the most
frequent (46.7%) resistance gene in the MRSA strains isolated from burn patients.
In addition, none of the MRSA isolates had the ermB gene that was in line with the
report by Lina et al. [27]. These findings were in disagreement with the study by
Fasihi et al. [28] performed in Kerman, Iran, in which an incidence of 11% and
3.5% was reported for ermA and ermB genes, respectively. It has been reported
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that the prevalence of the ermB in staphylococci isolated from animal sources is
higher than those isolated from human specimens [29].
Furthermore, the erm and msr genes have been reported in Denmark, the
United Kingdom, and Tunisia. In Tunisia and Denmark, ermB and ermA genes
were the most common clindamycin- and erythromycin-resistant genes, respec-
tively, but in this study, ermC was the most common [28]. In this study, according
to the results of PCR, the prevalence of ermC gene was lower than that of the ermA
and msrA genes, whereas most studies report ermC as the most frequent genetic
determinant [30, 31]. Regarding msrA, we found the incidence rate of 38.3% in
MRSA isolates. In a study from Serbia, the msrA was the most common resistance
gene [32].
The dissimilarities in the prevalence rate of MLSB resistance genes in
different studies may be explained by the heterogeneous nature of erythromycin
resistance, or it may be due to the loss of small plasmids that carry erm and msr
genes [28]. We identified the ermA+msrA+ ermC gene combinations in
28.3% of the MRSA isolates. Similarly, the simultaneous presence of two or
more MLSB resistance genes has been reported in previous studies from different
countries [33, 34].
Conclusions
This study has investigated the frequency of MLSB resistance genes in
MRSA strains isolated from burn patients using PCR method. This was the first
study to investigate the frequency of these genes in MRSA isolated from burn
patients in our region, which demonstrated the ermA gene as the most common
MLSB resistance gene among erythromycin-resistant isolates.
Because of the high prevalence of macrolide and lincosamide resistance
found in MRSA isolates from infections of burn patients in Ahvaz, Iran, a
knowledge about susceptibility patterns may provide crucial information for
controlling the dissemination of antimicrobial resistance and it is recommended
that local periodic survey be performed.
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